Esophagitis
diseaseOn this page
Also known as acute esophagitisesophagitis (disease)esophagus inflammationinflammation of esophagusinflammation of oesophagusoesophagus inflammation
Summary
Esophagitis (MONDO:0001409) is a disease (an umbrella term covering 6 Mondo subtypes) and 41 clinical trials. Top therapeutic interventions include domperidone, lansoprazole, and amifostine. A subtype of esophageal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 41
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | esophagitis |
| Mondo ID | MONDO:0001409 |
| MeSH | D004941 |
| DOID | DOID:11963 |
| ICD-10-CM | K20 |
| ICD-11 | 1540965840 |
| NCIT | C9224 |
| SNOMED CT | 16761005 |
| UMLS | C0014868 |
| MedGen | 4549 |
| Is cancer (heuristic) | no |
Also known as: acute esophagitis · esophagitis · esophagitis (disease) · esophagus inflammation · inflammation of esophagus · inflammation of oesophagus · oesophagus inflammation
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of esophageal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › upper digestive tract disorder › esophageal disorder › esophagitis
Related subtypes (19): esophageal atresia, esophageal varices, megaesophagus, esophageal tuberculosis, esophageal leukoplakia, dyskinesia of esophagus, esophageal diverticulosis, gastroesophageal reflux disease, esophageal atresia/tracheoesophageal fistula, achalasia, Barrett esophagus, esophageal duplication cyst, tubular duplication of the esophagus, laryngotracheoesophageal cleft, isolated tracheo-esophageal fistula, congenital esophageal diverticulum, neoplasm of esophagus, esophageal ulcer, congenital esophageal stenosis
Subtypes (6): fungal esophagitis, bacterial esophagitis, viral esophagitis, eosinophilic esophagitis, peptic esophagitis, Crohn disease of the esophagus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
4 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Dexlansoprazole | Approved (phase 4) |
| Famotidine | Approved (phase 4) |
| Nizatidine | Approved (phase 4) |
| Omeprazole | Approved (phase 4) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Avasopasem Manganese, Pantoprazole, Sucralfate.
Clinical trials & evidence
Clinical trials
Clinical trials: 41.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 21 |
| PHASE2 | 12 |
| PHASE4 | 2 |
| PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00133770 | PHASE4 | COMPLETED | Intravenous (IV) Pantoprazole in Erosive Esophagitis |
| NCT00872755 | PHASE4 | COMPLETED | Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) |
| NCT01696734 | PHASE3 | RECRUITING | Domperidone in Treating Patients With Gastrointestinal Disorders |
| NCT00195208 | PHASE3 | COMPLETED | Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis |
| NCT00081315 | PHASE2 | COMPLETED | Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer |
| NCT00123630 | PHASE2 | COMPLETED | A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab |
| NCT00123656 | PHASE2 | COMPLETED | Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis |
| NCT00175045 | PHASE2 | COMPLETED | Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis |
| NCT00471094 | PHASE2 | COMPLETED | Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis |
| NCT00523354 | PHASE2 | COMPLETED | Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis |
| NCT01262560 | PHASE2 | COMPLETED | Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer |
| NCT02575391 | PHASE1/PHASE2 | TERMINATED | The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer |
| NCT02577393 | PHASE2 | UNKNOWN | Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy |
| NCT04225026 | PHASE2 | TERMINATED | Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer |
| NCT04821310 | PHASE2 | TERMINATED | Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years |
| NCT05604261 | PHASE2 | UNKNOWN | A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis |
| NCT06392971 | PHASE2 | UNKNOWN | Deep-sea Fish Oil for Prevention of Acute Radiation-induced Esophagitis |
| NCT00216788 | PHASE1 | UNKNOWN | The Effect of Nexium on Transmucosal Esophageal Leak |
| NCT00284908 | PHASE1 | COMPLETED | Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers |
| NCT01824199 | EARLY_PHASE1 | WITHDRAWN | CYP2C19 Genotype Predictor of Gastric Acid Suppression |
| NCT03853772 | Not specified | ENROLLING_BY_INVITATION | The Johns Hopkins Heartburn Center Registry |
| NCT00256529 | Not specified | COMPLETED | Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia |
| NCT00272818 | Not specified | COMPLETED | Study to Identify Non-Invasive Markers of Gastrointestinal Allergy |
| NCT00579410 | Not specified | COMPLETED | Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule |
| NCT00677378 | Not specified | COMPLETED | Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain |
| NCT00761254 | Not specified | TERMINATED | Domperidone for Relief of Gastrointestinal Disorders |
| NCT00842387 | Not specified | COMPLETED | Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD) |
| NCT01322633 | Not specified | COMPLETED | Risk of Cancer Among Pantoprazole Users |
| NCT01323803 | Not specified | COMPLETED | Eosinophilic Esophagitis Databank |
| NCT01556919 | Not specified | COMPLETED | Esophageal Monitoring Device for Assessing Mucosal Impedance |
| NCT01733810 | Not specified | COMPLETED | The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis |
| NCT02100189 | Not specified | COMPLETED | Esophageal Cytology With FISH in Detecting Esophageal Cancer |
| NCT03228147 | Not specified | COMPLETED | Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment |
| NCT03619408 | Not specified | UNKNOWN | Management of Esophagitis Following Repair of Esophageal Atresia |
| NCT03835663 | Not specified | UNKNOWN | The Bacterial Composition of the Stomach in Reflux Disease |
| NCT04070677 | Not specified | UNKNOWN | Clinical Study Assessing the Effect of ZIVEREL® in Cancer Patients |
| NCT04252144 | Not specified | UNKNOWN | Study of Dietary Patterns and Food Diversity in Russian GERD Patients |
| NCT05004155 | Not specified | UNKNOWN | Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population |
| NCT05109819 | Not specified | UNKNOWN | Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression. |
| NCT05129670 | Not specified | COMPLETED | Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DOMPERIDONE | 4 | 2 |
| LANSOPRAZOLE | 4 | 2 |
| AMIFOSTINE | 4 | 1 |
| OMALIZUMAB | 4 | 1 |
| PANTOPRAZOLE | 4 | 1 |
| RABEPRAZOLE | 4 | 1 |
| ANAPRAZOLE | 3 | 1 |
| FLUTICASONE | 3 | 1 |
| ILAPRAZOLE | 3 | 1 |